Paul Hastings Advises Cell Signaling Technology in its Joint Commercialization Partnership with Astellas Pharma

March 01, 2011

Tokyo (March 2, 2011) Paul, Hastings, Janofsky & Walker LLP, a leading global law firm, is pleased to announce that it has advised Cell Signaling Technology, Inc. (CST), a leader in the development and manufacturing of high performance antibody products for the medical research and clinical diagnostic markets, in its joint commercialization partnership with Japans Astellas Pharma, Inc. (Astellas).

Under this agreement, CST and Astellas have combined their intellectual property estates relating to the fusion kinase, EML4-ALK, to enable the commercialization of diagnostic and therapeutic products targeting this cancer enzyme. The partnership provides each party with the right to exploit joint intellectual property estates and will encourage the development of products targeting EML4-ALK.

The Paul Hastings team was led by partner Ted Johnson.

Paul, Hastings, Janofsky & Walker LLP is a leading international law firm with offices in Asia, Europe, and the United States. We provide innovative legal solutions to financial institutions and Fortune 500 companies. Please visit www.paulhastings.com for more information.